BR112022012846A2 - Métodos de tratamento de condições relacionadas ao receptor s1p1 - Google Patents

Métodos de tratamento de condições relacionadas ao receptor s1p1

Info

Publication number
BR112022012846A2
BR112022012846A2 BR112022012846A BR112022012846A BR112022012846A2 BR 112022012846 A2 BR112022012846 A2 BR 112022012846A2 BR 112022012846 A BR112022012846 A BR 112022012846A BR 112022012846 A BR112022012846 A BR 112022012846A BR 112022012846 A2 BR112022012846 A2 BR 112022012846A2
Authority
BR
Brazil
Prior art keywords
methods
treatment
conditions related
receiver
acid
Prior art date
Application number
BR112022012846A
Other languages
English (en)
Inventor
M Crosby Catherine
Ahluwalia Gurpreet
Christopher Wesley Selfridge Andrew
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of BR112022012846A2 publication Critical patent/BR112022012846A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Heat Treatment Of Sheet Steel (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Steering-Linkage Mechanisms And Four-Wheel Steering (AREA)
  • Medicinal Preparation (AREA)

Abstract

MÉTODOS DE TRATAMENTO DE CONDIÇÕES RELACIONADAS AO RECEPTOR S1P1. A presente invenção refere-se a métodos de tratamento de alopecia areata que compreendem prescrever e/ou administrar a um indivíduo em necessidade do mesmo uma dose padrão de ácido (R)-2-(7-(4-ciclopentil-3-(trifluormetil)benzilóxi)-1,2,3,4-tetra-hidrociclopenta[b]indol-3-il)acético (Composto 1), ou um sal farmaceuticamente aceitável do mesmo.
BR112022012846A 2020-01-06 2021-01-06 Métodos de tratamento de condições relacionadas ao receptor s1p1 BR112022012846A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062957535P 2020-01-06 2020-01-06
PCT/US2021/012367 WO2021142030A1 (en) 2020-01-06 2021-01-06 Methods of treating conditions related to the s1p1 receptor

Publications (1)

Publication Number Publication Date
BR112022012846A2 true BR112022012846A2 (pt) 2022-09-06

Family

ID=76788331

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012846A BR112022012846A2 (pt) 2020-01-06 2021-01-06 Métodos de tratamento de condições relacionadas ao receptor s1p1

Country Status (12)

Country Link
US (1) US20230338336A1 (pt)
EP (1) EP4087562A4 (pt)
JP (1) JP2023509698A (pt)
KR (1) KR20220124209A (pt)
CN (1) CN115066242A (pt)
AU (1) AU2021205465A1 (pt)
BR (1) BR112022012846A2 (pt)
CA (1) CA3166828A1 (pt)
IL (1) IL294071A (pt)
MX (1) MX2022008342A (pt)
TW (1) TW202135804A (pt)
WO (1) WO2021142030A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023049241A1 (en) * 2021-09-23 2023-03-30 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
WO2023135506A1 (en) * 2022-01-13 2023-07-20 Arena Pharmaceuticals, Inc. Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment
CA3213748A1 (en) 2022-10-21 2023-12-08 Bongyong Lee Pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for s1pr1 and s1pr4
KR102541577B1 (ko) * 2022-10-21 2023-06-13 주식회사 넥스트젠바이오사이언스 S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061567A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
BR112012011427B8 (pt) * 2009-11-13 2021-05-25 Celgene Int Ii Sarl moduladores seletivos de receptor de esfingosina 1 fosfato, seu uso, e composição
US9198911B2 (en) * 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
AU2016205361C1 (en) * 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11534424B2 (en) * 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis

Also Published As

Publication number Publication date
IL294071A (en) 2022-08-01
MX2022008342A (es) 2022-08-04
CA3166828A1 (en) 2021-07-15
WO2021142030A1 (en) 2021-07-15
KR20220124209A (ko) 2022-09-13
JP2023509698A (ja) 2023-03-09
AU2021205465A1 (en) 2022-07-14
CN115066242A (zh) 2022-09-16
TW202135804A (zh) 2021-10-01
EP4087562A4 (en) 2024-01-10
EP4087562A1 (en) 2022-11-16
US20230338336A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
BR112022012846A2 (pt) Métodos de tratamento de condições relacionadas ao receptor s1p1
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
CY1118313T1 (el) Παραγωγα καρβοστυρυλιου και σταθεροποιητες της διαθεσης για αντιμετωπιση διαταραχων της διαθεσης
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
MX2020013157A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
AU2003256755A8 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
BR0011823A (pt) Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
MX2009002921A (es) Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
MA40769B1 (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MX2022008181A (es) Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia.
JOP20190008A1 (ar) علاج ومنع اضطرابات النوم
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
BRPI0515954A (pt) composto e sais farmaceuticamente aceitáveis do mesmo e enanciÈmeros e diaestereÈmeros individuais do mesmo, composição farmacêutica, e, métodos para inibição do transportador de glicina glyt1 em um mamìfero, para a fabricação de um medicamento para inibir o transportador de glicina glyt1 em um mamìfero, para tratar um distúbios neurológicos e psiquiátricos associados com disfunçao de neurotransmissão glicinérgica ou glutamatérgica em um paciente mamìfero e para tratar esquizofrenia em um paciente mamìfero
BR112022007348A2 (pt) Métodos para tratar condições relacionadas ao receptor s1p1
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
CY1124236T1 (el) Διαλυμα εγχυσης λεβοντοπα
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
BR112022005999A2 (pt) Métodos de tratamento de condições relacionadas ao receptor s1p1
BR0312929A (pt) Uso de um composto, e, métodos de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo, e da degeneração macular relacionada com a idade de um corpo de animal vivo
EA202290027A1 (ru) Способы и композиции для улучшения результатов лечения пациентов с раком
BR112019000509A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ARENA PHARMACEUTICALS, INC. (US)